Patients
Sites
Sponsors
About Us
News
Sites access
Onco access
EN
Last updated 37 hours ago
Share
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
1280 patients around the world
Available in
Puerto Rico, Guatemala, United States, Mexico
AbbVie
2
Research sites
1280
Patients around the world
This study is for people with
Hidradenitis suppurativa
Requirements for the patient
From 12 Years
All Gender
Medical requirements
Inclusion criteria
Diagnosis of moderate to severe HS for at least 6 months prior to Baseline as determined by the investigator.
Total abscess and inflammatory nodule count of ≥ 5 at Baseline.
Hidradenitis suppurativa lesions present in at least two distinct anatomic areas at Baseline.
At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher at Baseline.
Exclusion criteria
Any evidence of Hepatitis B virus or hepatitis C virus infection.
Confirmed positive anti-HIV antibody test.
Evidence of active tuberculosis or meets tuberculosis exclusionary parameter.
Sites
Dermos
Recruiting
Consult
View site
Zone 15, Guatemala City, Guatemala
View site
Consult
Eukarya PharmaSite
Recruiting
Consult
View site
De La Clínica 2520, Sertoma, 64718 Monterrey, N.L.
View site
Consult
See details
Contact us
Contact us
Study
Intrepid
Sponsor
AbbVie
Study type
Interventional
Conditions
Hidradenitis suppurativa
Requirements
From 12 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT06468228
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent